Tag: Lord Mancroft

The below Parliamentary question was asked by Lord Mancroft on 2016-02-09.

To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 4 January (HL4665) about access to hepatitis C treatment, how frequently NHS England will publish reports on the minimum data set and when the first set of data on patients being treated will be published.

Lord Prior of Brampton

Public Health England (PHE) is working with NHS England and the Clinical Leads of the Operational Delivery Networks to ensure that a minimum data set is collected to allow monitoring of patients being treated. This will be used to support commissioning and planning of these services. PHE plans to publish summary data on people being treated in the annual report on hepatitis C. No timetable for publication has been agreed.

The below Parliamentary question was asked by Lord Mancroft on 2016-04-13.

To ask Her Majesty’s Government whether NHS England’s decision to treat 10,000 hepatitis C patients represents a cap on the number of patients the NHS can treat in 2016–17.

Lord Prior of Brampton

NHS England’s approach paces the roll-out of hepatitis C treatment in accordance with the National Institute for Health and Care Excellence (NICE) recommendation for prioritisation and the modelling assumptions which informed the NICE recommendations.

The below Parliamentary question was asked by Lord Mancroft on 2016-02-09.

To ask Her Majesty’s Government what steps they are taking to develop prison health workers’ understanding of the prevention, diagnosis and treatment of hepatitis C.

Lord Prior of Brampton

NHS England, Public Heath England, the National Offender Management Service and other organisations including the Royal College of General Practitioners have developed resources to support prison healthcare teams in delivering a blood-borne virus (BBV) opt-out testing programme. This covers all aspects of prevention, diagnosis and treatment of hepatitis C (HCV) and other BBVs including testing, managing positive and negative test results, providing advice on harm minimisation and supporting prisoners into treatment.

Specialised HCV Operational Delivery Networks (ODNs) ensure specialist oversight of HCV services in order maximise uptake and completion of HCV treatment. NHS England has linked every prison to the relevant ODN and a service specification for ODNs directs specialist service providers to accept patients from prisons.

The below Parliamentary question was asked by Lord Mancroft on 2016-04-13.

To ask Her Majesty’s Government whether patients who meet the eligibility criteria for NICE-approved medicines for hepatitis C will have access to treatment in line with their rights under the NHS Constitution in 2016–17, even if more than 10,000 patients have already been treated.

Lord Prior of Brampton

NHS England’s approach paces the roll-out of hepatitis C treatment in accordance with the National Institute for Health and Care Excellence (NICE) recommendation for prioritisation and the modelling assumptions which informed the NICE recommendations. These are in line with patients’ rights under the NHS Constitution.

The below Parliamentary question was asked by Lord Mancroft on 2016-02-09.

To ask Her Majesty’s Government what progress Operational Delivery Networks have made in establishing services for prisoners diagnosed with hepatitis C.

Lord Prior of Brampton

NHS England, Public Heath England, the National Offender Management Service and other organisations including the Royal College of General Practitioners have developed resources to support prison healthcare teams in delivering a blood-borne virus (BBV) opt-out testing programme. This covers all aspects of prevention, diagnosis and treatment of hepatitis C (HCV) and other BBVs including testing, managing positive and negative test results, providing advice on harm minimisation and supporting prisoners into treatment.

Specialised HCV Operational Delivery Networks (ODNs) ensure specialist oversight of HCV services in order maximise uptake and completion of HCV treatment. NHS England has linked every prison to the relevant ODN and a service specification for ODNs directs specialist service providers to accept patients from prisons.

The below Parliamentary question was asked by Lord Mancroft on 2016-04-13.

To ask Her Majesty’s Government on what basis, if any, the NHS Mandate requires that investment in NICE-recommended treatments for hepatitis C be limited to avoid disinvestment in other health services.

Lord Prior of Brampton

The NHS Mandate requires healthcare expenditure to be limited to the resources made available by the government. The range of potential treatments which could improve patients health exceeds the funding made available to the National Health Service, therefore increased investment in one area has an opportunity cost on the ability to invest in other areas. NHS England is investing in the rollout of Hepatitis C treatment in full accordance with National Institute of Health and Care Excellence guidance, with an expected doubling of the number of patients benefiting from new treatment to 10,000s in the coming year.

The below Parliamentary question was asked by Lord Mancroft on 2016-03-23.

To ask Her Majesty’s Government how many hepatitis C patients NHS England is planning to treat in 2016–17.

Lord Prior of Brampton

NHS England is planning to treat 10,000 patients with chronic hepatitis C in 2016/2017.

The below Parliamentary question was asked by Lord Mancroft on 2016-04-13.

To ask Her Majesty’s Government what is the breakdown of the patient treatment capacity for each Operational Delivery Network for hepatitis C, broken down by hub and spoke.

Lord Prior of Brampton

NHS England does not hold this information. NHS England is not the responsible commissioner for all services in which the treatment of people with hepatitis is undertaken.

The below Parliamentary question was asked by Lord Mancroft on 2016-03-23.

To ask Her Majesty’s Government for what reason NHS England intends to treat only a specified number of patients in 2016–17, as defined by recently published run rates for operational delivery networks services.

Lord Prior of Brampton

The National Institute for Health and Care Excellence (NICE) specifically requires Operational Delivery Networks (ODNs) to prioritise hepatitis C patients on the basis of highest unmet clinical need, as part of a progressive rollout of treatments over the next five years.

NHS England is funding providers to double the number of patients treated and this number will ensure the National Health Service fully meets in 2016/17 the patient numbers NICE set out for progressive rollout of the treatments at the time it published its guidance.

NHS England has invested in a Commissioning for Quality and Innovation scheme to incentivise ODNs to meet their agreed rate of roll-out. If their treatment rates deviate from this agreed rate of treatment, they are no longer eligible for these incentives.

In meeting the obligations of its Mandate, NHS England has set out a planning approach for hepatitis C that delivers access to NICE recommended treatment without disinvestment in other health services.

The below Parliamentary question was asked by Lord Mancroft on 2016-04-13.

To ask Her Majesty’s Government what is the breakdown of run rates assigned to each Operational Delivery Network for hepatitis C, broken down by hub and spoke.

Lord Prior of Brampton

Operational Delivery Networks (ODNs) lead organisations in collaboration with the local NHS England commissioning team are responsible for approving the organisations involved in the ODN. The ODN lead provider is responsible for working with its partners in determining how the patient numbers will be managed across its network. NHS England does not hold this information.